TCR mimics (TCRm) and engineered TCRs enable drug developers to work against the vast space of intracellular proteins (>70% of the human proteome) that have not been addressed by conventional cancer immunotherapies. Despite tremendous potential therapeutic values, the discovery of highly specific TCRm and TCR-based therapeutics remains a challenge for many due to inaccessibility to the required foundational technologies. Alloy’s Keyway TCR Discovery group provides comprehensive proprietary technology and capabilities for the end-to-end discovery of these modalities. In this webinar, leading scientists at the helm of Keyway TCRm Discovery campaigns will present:

 

 

1. An overview of common challenges to intracellular protein-targeting drug discovery

2. Keyway’s industry-leading solutions to TCRm/TCR-based therapeutic discovery including its proprietary specificity screening and high-quality pMHC complex antigen production capabilities

3. A case study featuring the discovery of a panel of highly specific, functional TCRm binders against an intracellular immuno-oncology target

 

Join us for an informative discussion, and be sure to bring your questions.